Trials / Completed
CompletedNCT00141960
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 480 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents. While most of the patients given the diagnosis of GERD do not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have subjective symptoms of non-erosive GERD including heartburn. But no drug has been launched in Japan, which targets non-erosive GERD. This study will examine the efficacy and safety of famotidine in subjects with non-erosive GERD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famotidine |
Timeline
- Start date
- 2005-09-01
- First posted
- 2005-09-02
- Last updated
- 2011-11-21
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00141960. Inclusion in this directory is not an endorsement.